Mouse-adapted SARS-CoV-2 replicates efficiently in the upper and lower respiratory tract of BALB/c and C57BL/6J mice

References

[1] Bao L, Deng W, Huang B, Gao H, Liu J, Ren L, Wei Q, Yu P, Xu Y, Qi F (2020) The pathogenicity of SARS-CoV-1 2 in hACE2 transgenic mice. Nature. https://doi.org/10.1038/s41586-020-2312-y

[2] Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S (2020) Remdesivir for the treatment of Covid-19- preliminary report. N Engl J Med. https://doi.org/10.1056/NEJMoa2007764

[3] Dinnon KH III, Leist SR, Schafer A, Edwards CE, Martinez DR, Montgomery SA, West A, Yount BL, Hou YJ, Adams LE, Gully KL (2020) A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures. bioRxiv. https://doi.org/10.1101/20200506081497

[4] Gu H, Chen Q, Yang G, He L, Fan H, Deng Y-Q, Wang Y, Teng Y, Zhao Z, Cui Y (2020) Rapid adaptation of SARS-CoV-2 in BALB/c mice: novel mouse model for vaccine efficacy. bioRxiv. https://dottps://doii.org/10.1.org/10.11101/202005001/202005022073410734111

[5] Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC (2020) Clinical Characteristics of Coronavirus disease 2019 in China. N Engl J Med 382:1708–1720

[6] Hassan AO, Case JB, Winkler ES, Thackray L, Kafai NM, Bailey AL, McCune BT, Fox JM, Chen RE, Soussi WBA (2020) A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies. Cell. https://doi.org/10.1016/jcell202006011

[7] Jiang R-D, Liu M-Q, Chen Y, Shan C, Zhou Y-W, Shen X-R, Li Q, Zhang L, Zhu Y, Si H-R (2020) Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensinconverting enzyme 2. Cell. https://doi.org/10.1016/jcell202005027

[8] Kirchdoerfer RN, Ward AB (2019) Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nat Commun 10:2342

[9] Liu Z, Zheng H, Yuan R, Li M, Lin H, Peng J, Xiong Q, Sun J, Li B, Wu J (2020) Identification of a common deletion in the spike protein of SARS-CoV-2. bioRxiv. https://doi.org/10.1101/20200331015941

[10] Sun J, Zhuang Z, Zheng J, Li K, Wong RL, Liu D, Huang J, He J, Zhu A, Zhao J, Li X (2020) Generation of a broadly useful model for COVID-19 pathogenesis vaccination, and treatment. Cell. https://doi.org/10.1016/jcell202006010

[11] Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G (2020a) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269–271

[12] Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q (2020b) Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395:1569–1578

[13] World Health Organization (2020) Coronavirus disease (COVID-2019) situation report for 30 June 2020. https://www.who.int/docs/default-source/coronaviruse/20200630-covid-19-sitrep-162.pdf?sfvrsn=e00a5466_2

[14] Zhou H, Chen X, Hu T, Li J, Song H, Liu Y, Wang P, Liu D, Yang J, Holmes EC (2020) A novel bat coronavirus reveals natural insertions at the S1/S2 cleavage site of the Spike protein and a possible recombinant origin of HCoV-19. bioRxiv. https://doi.org/10.1101/20200302974139

RIGHTS & PERMISSIONS

2020 The Author(s)